10-K: Walgreens Boots Alliance Reports Fiscal Year 2024 Results Amidst Strategic Review

Walgreens Boots Alliance reports a net loss for fiscal year 2024, impacted by significant impairment charges and a challenging retail environment, while initiating a strategic review to optimize its portfolio.

Summary

• Walgreens Boots Alliance (WBA) reported a net loss of $8.6 billion for fiscal year 2024, a significant increase from the $3.1 billion loss in the previous year.
• The company's operating loss was $14.1 billion, compared to $6.9 billion in the prior year, primarily due to a $12.4 billion non-cash impairment charge related to VillageMD goodwill.
• Adjusted operating income decreased by 32.2% to $2.6 billion, reflecting challenges in the U.S. retail environment and reimbursement pressures.
• Total sales for fiscal year 2024 reached $147.7 billion, a 6.2% increase year-over-year, driven mainly by pharmacy sales.
• The U.S. Retail Pharmacy segment saw a 5% increase in sales to $115.8 billion, while the International segment's sales rose by 6.1% to $23.6 billion.
• The U.S. Healthcare segment's sales increased to $8.3 billion, driven by growth in VillageMD and Shields.
• WBA filled 796 million prescriptions in the U.S. Retail Pharmacy segment, or 1.2 billion adjusted to 30-day equivalents.
• The company is implementing a Footprint Optimization Program to close 900 to 1,000 underperforming stores, primarily in the U.S., by the end of fiscal 2027.
• WBA has completed its Transformational Cost Management Program, achieving $4.5 billion in annual cost savings by the end of fiscal 2024.

Sentiment

Score: 3

Explanation: The document reflects a negative sentiment due to significant losses, impairment charges, and a challenging retail environment. While the company is taking steps to address these issues, the overall tone is cautious and reflects a need for significant improvements.

Positives

• Total sales increased by 6.2% to $147.7 billion, driven by pharmacy sales.
• The U.S. Healthcare segment saw significant sales growth, driven by VillageMD and Shields.
• The company has completed its Transformational Cost Management Program, achieving $4.5 billion in annual cost savings.
• The company reduced net debt by nearly $2.0 billion and lease obligations by over $1.0 billion in fiscal 2024.
• The company met its goals by reducing capital expenditures by over $700 million and realizing over $600 million in benefits from working capital initiatives.

Negatives

• The company reported a net loss of $8.6 billion for fiscal year 2024.
• Operating loss increased to $14.1 billion, primarily due to a $12.4 billion non-cash impairment charge related to VillageMD goodwill.
• Adjusted operating income decreased by 32.2% to $2.6 billion.
• The U.S. Retail Pharmacy segment experienced lower retail scan volume, elevated shrink levels, and continued net reimbursement pressure.
• The company experienced lower reimbursement rates in fiscal 2024 as compared to the prior year.

Risks

• Changes in economic conditions could adversely affect consumer buying practices.
• Reductions in third-party reimbursement levels and potential changes in industry pricing benchmarks for prescription drugs could materially and adversely affect results of operations.
• The U.S. Healthcare segment faces various risks related to the provision of healthcare services that could result in a material adverse effect on business operations, results of operations and financial condition.
• The company may not be successful in executing elements of its business strategy, which may have a material adverse impact on business and financial results.
• The company is subject to evolving ESG and climate-related regulatory requirements and may be unable to meet standards.
• Disruptions in the global supply chain could negatively impact the ability to provide products and services to customers and could impact financial performance.
• The company has significant outstanding debt; its debt and associated payment obligations could significantly increase in the future if it incurs additional debt and does not retire existing debt.
• The company has a substantial amount of goodwill and other intangible assets that have become impaired and could, in the future, become further impaired, resulting in material non-cash charges to results of operations.

Future Outlook

The company expects to focus on areas that build its core retail and specialty pharmacy business, leverage its current assets through capital-efficient businesses, and expand its relationships with business partners. The company is also evaluating options with respect to its investment in VillageMD, including a potential sale or restructuring.

Management Comments

• The company is analyzing opportunities that may impact the future results of operations and cash flows, including the Companys recently approved plan to implement a significant multi-year U.S. Footprint Optimization Program to close certain underperforming stores, primarily in the U.S.
• The company is re-evaluating the U.S. Retail Pharmacy sales strategy, including the merchandising strategy, in an effort to offer a refreshed assortment of products, with a planned focus of being more selective with national brands and expanding owned brands in key categories.
• The company is stabilizing pharmacy margins by collaborating and negotiating with pharmacy benefit managers (PBMs) in an attempt to bring more stability and predictability to retail pharmacy reimbursement models.
• The company is re-evaluating capital allocation priorities, including an assessment of our dividend policy.
• The company is continuing to focus on monetizing non-core assets to generate cash flow and harvesting gains from our portfolio of investments, such as Cencora and BrightSpring Health Services.
• The company is simplifying and focusing the U.S. Healthcare portfolio.

Industry Context

The retail pharmacy industry is highly competitive and dynamic, with approximately 40,000 retail locations throughout the U.S. The industry is facing ongoing reimbursement pressures from third-party payors and governmental agencies, as well as the impact of the Inflation Reduction Act of 2022. The healthcare services sector is also undergoing transformation, with a growing demand for convenient, accessible, and affordable care.

Comparison to Industry Standards

• Walgreens Boots Alliance's performance is being compared to other major retail pharmacy chains such as CVS Health and Rite Aid, as well as to other healthcare providers and pharmacy benefit managers.
• The company's strategic review and cost-cutting measures are similar to actions taken by other companies in the industry to adapt to changing market conditions and reimbursement pressures.
• The company's focus on expanding healthcare services and value-based care models aligns with broader industry trends.
• The company's impairment charges related to VillageMD are significant and may be compared to similar write-downs by other companies in the healthcare sector.

Management Changes

Legal Proceedings

• The company has accrued a total of $6.6 billion liability associated with the Multistate Agreement and other opioid-related claims and litigation settlements.
• The company remains a defendant in multiple actions in federal courts alleging claims generally concerning the impacts of widespread opioid abuse.
• The company is involved in legal proceedings, including litigation, arbitration and other claims, and investigations, inspections, audits, claims, inquiries and similar actions by pharmacy, healthcare, tax and other governmental authorities.

Related Party Transactions

• The company has a long-term pharmaceutical distribution agreement with Cencora pursuant to which the company sources branded and generic pharmaceutical products from Cencora.
• The company also has an agreement which provides Cencora the ability to access generic pharmaceutical products through the company's global sourcing enterprise.

Stakeholder Impact

• Shareholders are negatively impacted by the net loss and decreased adjusted operating income.
• Employees may be affected by the Footprint Optimization Program and potential restructuring activities.
• Customers may experience changes in store locations and service offerings.
• Suppliers and creditors may be impacted by the company's strategic review and potential asset divestitures.

Next Steps

• The company will implement the Footprint Optimization Program to close 900 to 1,000 underperforming stores by the end of fiscal 2027.
• The company will continue to evaluate its overall portfolio of assets and investments and may take action in line with the Companys strategic direction.
• The company is actively engaged in discussions with VillageMDs stakeholders and other third parties with respect to the future of its investment in VillageMD.
• The company will continue to focus on monetizing non-core assets to generate cash flow and harvesting gains from its portfolio of investments, such as Cencora and BrightSpring Health Services.

Key Dates

Keywords

Walgreens Boots Alliance, WBA, pharmacy, healthcare, retail, financial results, impairment, VillageMD, reimbursement, cost savings, strategic review, prescription drugs, operating income, net loss, debt, store closures